株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

スタチン:世界市場の見通し(2011〜2021年)

Statins: World Market Outlook 2011-2021

発行 Visiongain Ltd 商品コード 191133
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=146.92円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
スタチン:世界市場の見通し(2011〜2021年) Statins: World Market Outlook 2011-2021
出版日: 2011年03月30日 ページ情報: 英文 150 Pages
概要

2009年、世界のスタチン市場は270億米ドルの収益を上げました。2011〜2021年にかけ、LipitorやCrestorの特許失効により、ジェネリック薬との競争が激しくなることが予想されます。スタチンのブランド薬市場は今後衰退する見通しとなっています。

当レポートでは、スタチンの2011〜2021年の市場収益予測、研究開発動向、市場シェア、SWOT分析などをまとめ、概略以下の構成でお届けいたします。

第1章 エグゼクティブ・サマリー

第2章 脂質異常症と冠動脈疾患

  • コレステロールとトリグリセリド
  • コレステロールとトリグリセリドの輸送因子としてのリポタンパク質
  • 脂質異常症とアテローム性動脈硬化
  • コレステロールのリスクレベル
  • 脂質異常症に対するFredrickson/WHOの分類
  • 心血管疾患
  • 冠動脈疾患のリスクファクター
  • コレステロール検査
  • アテローム性動脈硬化の一次、二次予防

第3章 スタチンとその他の脂質低下薬剤

  • スタチン:種類と作用機序
  • Atorvastatin
  • Rosuvastatin
  • Simvastatin
  • Pravastatin
  • Fluvastatin
  • Pitavastatin
  • Lovastatin
  • スタチンと非スタチンの併用薬
  • その他

第4章 世界のスタチン市場サマリー:2011〜2021年

  • 概要
  • 売上減少動向
  • ジェネリック薬が市場を独占
  • インドと中国の市場成長:2011〜2021年

第5章 世界のスタチン市場:2011〜2021年

第6章 主要国市場:2011〜2021年

第7章 世界のスタチン市場影響因子分析:2011〜2021年

  • SWOT分析
  • 促進因子と阻害因子
  • 今後の見通し
  • 患者適合性
  • スタチンの安全性
  • スタチンのスイッチOTC
  • 世界のスタチン市場規模拡大における治験の役割

第8章 専門家インタビュー

第9章 スタチンと非スタチン剤研究開発パイプライン

第10章 結論

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

-what will happen now in the statin drugs market?

What does the future hold for the statins industry and market? Our new report shows how the patent expiry of Lipitor and others will affect statin drug revenues from 2011 onwards.

Our report gives you revenue forecasts for statin drugs from 2011 to 2021. We aim to save you time and aid your decisions through our research, data and discussions. By ordering now, you can stay ahead.

In 2009 the world statins market generated over $27bn in revenues. We show the organisations, products and activities that will shape the statins industry and market this decade.

What revenues will statin drug forms achieve from 2011 to 2021? What revenues can leading products - such as Lipitor and Crestor - achieve? What revenue trends will national markets show? How will generic sales take off?

Our new study answers those questions and many others for lipid-lowering drugs. We show you what companies are doing, and how branded and generic competition is shaping up.

From 2011 to 2021 the patent expiries of Lipitor (atorvastatin) and Crestor (rosuvastatin) will lead to rising generic competition. The overall branded statins market looks set to decline. We show you by how much, and where generic and novel drug opportunities will be.

Our report gives you revenue forecasts at world, group, product and national levels. You will also see trends in dyslipidemia R&D. We analyse opportunities in coronary heart disease.

Here, you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Please respond now to get that information.

Analysis and expert opinion to help your work - so you won' t be left behind

Our report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and expert opinion. We include 80 tables and charts and two research interviews (shown in the accompanying lists).

We can help you now, making it easier for you to stay ahead in this market.

Statins: World Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

  • You will find hard data for the statins industry and market - seeing revenue trends
  • You will receive revenue forecasts for the global lipid-lowering drug market to 2021 - with statin and non-statin groups represented
  • You will find revenues for original-brand and generic statins from 2009 to 2021, with discussions of market potential and competition
  • You will discover revenue forecasts for atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, pitavastatin and lovastatin products to 2021
  • You will learn how the patent expiries of Lipitor and Crestor will affect the future of this therapeutic market
  • You will receive revenue forecasts for the leading national markets to 2021 (US, Canada, Japan, France, UK, Spain, Italy, Germany, Brazil, China and India)
  • You will examine research and development, as well as up-and-coming products
  • You will review under-met needs in the lipid-lowering drug market, with therapeutic requirements and commercial opportunities discussed
  • You will investigate strengths, competition and opportunities that will influence the statins industry and market from 2011 onwards
  • You will see what will stimulate and restrain the statins industry and market
  • You will analyse opportunities for established companies and those seeking to enter the dyslipidemia treatment market
  • You will view expert opinion from our survey, including full interview transcripts
  • You will discover where the statins industry and market are heading - technology, competition and revenues.

That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends - predictions found only in our work. Our independent analysis helps you to stay ahead in market knowledge.

1. Executive Summary

  • 1.1 Review of the World Statins Market
  • 1.2 Aims, Scope and Format of Report
  • 1.3 Research and Analysis Methods

2. Dyslipidaemia and Coronary Heart Disease

  • 2.1 Cholesterol and Triglycerides
  • 2.2 Lipoproteins as Transporters of Cholesterol and Triglycerides
  • 2.3 Dyslipidaemia and Atherosclerosis
  • 2.4 Cholesterol Risk Levels
  • 2.5 The Fredrickson/World Health Organization (WHO) Classification of Dyslipidaemia
  • 2.6 Cardiovascular Disease
  • 2.7 Risk Factors for Coronary Heart Disease
  • 2.8 Cholesterol Testing
  • 2.9 Primary and Secondary Prevention of Atherosclerosis

3. Statins and Other Lipid-Lowering Drugs

  • 3.1 Statins: Types and Mechanism of Action
  • 3.2 Atorvastatin
    • 3.2.1 Atorvastatin Indications
    • 3.2.2 Atorvastatin Brands and Generic Manufacturers
  • 3.3 Rosuvastatin
    • 3.3.1 Rosuvastatin Indications
    • 3.3.2 Rosuvastatin Brands and Generic Manufacturers
  • 3.4 Simvastatin
    • 3.4.1 Simvastatin Indications
    • 3.4.2 Simvastatin Brands and Generic Manufacturers
  • 3.5 Pravastatin
    • 3.5.1 Pravastatin Indications
    • 3.5.2 Pravastatin Brands and Generic Manufacturers
  • 3.6 Fluvastatin
    • 3.6.1 Fluvastatin Indications
    • 3.6.2 Fluvastatin Brands and Generic Manufacturers
  • 3.7 Pitavastatin
  • 3.8 Lovastatin
    • 3.8.1 Lovastatin Indications
    • 3.8.2 Lovastatin Brands and Generic Manufacturers
  • 3.9 Statin/Non-Statin Combination Drugs
    • 3.9.1 Lovastatin/Nicotinic Acid
    • 3.9.2 Simvastatin/Nicotinic Acid
    • 3.9.3 Simvastatin/Ezetimibe
    • 3.9.4 Caduet (atorvastatin/amlodipine)
  • 3.10 Other Lipid-Lowering Drugs
    • 3.10.1 Anion-Exchange Resins
    • 3.10.2 Ezetimibe
    • 3.10.3 Fibrates
    • 3.10.4 Nicotinic Acid
    • 3.10.5 Omega-3-Acid Ethyl Esters

4. Summary of the World Statins Market, 2011-2021

  • 4.1 Overview of the World Statins Market, 2011-2021
  • 4.2 World Statins Market Will See Declining Sales, 2009-2021
    • 4.2.1 The Lipitor Patent Cliff
    • 4.2.2 Pitavastatin Will See Growing Competition from Generic and More-Established Statin Brands
  • 4.3 Generic Products Set to Dominate the World Statins Market
  • 4.4 Statin Drug Markets in India and China Expected to Grow from 2011-2021

5. World Market for Statin Drugs, 2011-2021

  • 5.1 Statins are Leading Therapies in the Lipid-Lowering Market
    • 5.1.1 The World Lipid-Lowering Market
    • 5.1.2 World Lipid-Lowering Drug Market Forecasts, 2009-2021
  • 5.2 The World Statins Market
    • 5.2.1 The World Statins Market, 2009
    • 5.2.2 Scope for Further Growth: World Statins Market Forecasts, 2009-2010
    • 5.2.3 The Impact of Atorvastatin Generics on the World Statins Market, 2011-2015
    • 5.2.4 Opportunities for Generics Manufacturers: World Statins Market Forecasts, 2015-2019
    • 5.2.5 Prospects for the World Statins Market, 2020-2021
  • 5.3 The Branded and Generic Statins Markets
    • 5.3.1 The Branded and Generic Statins Markets, 2009
    • 5.3.2 When Will Sales of Generic Statins Exceed Branded Revenues?
  • 5.4 Statins Market Forecast by Drug Class, 2009-2021
    • 5.4.1 Will Atorvastatin Market Show Continuous Decline in Revenues from 2011-2021?
    • 5.4.2 Revenues of Rosuvastatin and Statin Combination Drugs Expected to Grow from 2011-2015
  • 5.5 Atorvastatin
    • 5.5.1 The Atorvastatin Market, 2009
    • 5.5.2 Atorvastatin Market Forecast, 2009-2021
    • 5.5.3 Lipitor Market Forecast, 2009-2021
    • 5.5.4 Prospects for Lipitor after Patent Expiry: Market Forecast, 2011-2015
    • 5.5.5 Lipitor Market Forecast, 2016-2021
    • 5.5.6 Generic Atorvastatin Market Forecast, 2009-2021
  • 5.6 Rosuvastatin
    • 5.6.1 The Rosuvastatin Market, 2009
    • 5.6.2 Rosuvastatin Market Forecast, 2009-2021
    • 5.6.3 Crestor Market Forecast, 2009-2021
    • 5.6.4 Generic Rosuvastatin Market, 2009-2021
  • 5.7 Simvastatin
    • 5.7.1 The Simvastatin Market, 2009
    • 5.7.2 Simvastatin Market Forecast, 2009-2021
    • 5.7.3 Zocor Market Forecast, 2009-2021
    • 5.7.4 Generic Simvastatin Market, 2009-2021
  • 5.8 Pravastatin
    • 5.8.1 The Pravastatin Market, 2009
    • 5.8.2 Pravastatin Market Forecast, 2009-2021
    • 5.8.3 Mevalotin/Pravachol Market Forecast, 2009-2021
    • 5.8.4 Generic Pravastatin Market, 2009-2021
  • 5.9 Fluvastatin
    • 5.9.1 The Fluvastatin Market, 2009
    • 5.9.2 Fluvastatin Market Forecast, 2009-2021
    • 5.9.3 Lescol/Lochol Market Forecast, 2009-2021
    • 5.9.4 Generic Fluvastatin Market, 2009-2021
  • 5.10 Pitavastatin
    • 5.10.1 The Pitavastatin Market, 2009
    • 5.10.2 Pitavastatin Market Forecast, 2009-2021
    • 5.10.3 Livalo Market Forecast, 2009-2021
    • 5.10.4 Generic Pitavastatin Market, 2009-2021
  • 5.11 Lovastatin
    • 5.11.1 The Lovastatin Market, 2009
    • 5.11.2 Lovastatin Market Forecast, 2009-2021
  • 5.12 Statin/Non-Statin Combination Drugs
    • 5.12.1 The Statin/Non-Statin Combination Market, 2009
    • 5.12.2 Statin Combination Market Will See Positive Growth in Market Size, 2009-2015
    • 5.12.3 Generic Drugs Will Dominate the Statin Combination Market, 2016-2021
    • 5.12.4 Vytorin/Inegy Market Forecast, 2009-2021
    • 5.12.5 Caduet Market Forecast, 2009-2021

6. Leading National Markets for Statin Drugs, 2011-2021

  • 6.1 Leading National Markets for Sales of Statins, 2009
  • 6.2 Sales Forecasts for the Leading National Markets, 2009-2021
    • 6.2.1 The Statins Market in the US, 2009-2021
    • 6.2.2 The Statins Market in Japan, 2009-2021
    • 6.2.3 The Statins Market in Canada, 2009-2021
    • 6.2.4 The Leading European Statins Markets, 2009-2021
    • 6.2.5 The Statins Markets in India and China, 2009-2021
    • 6.2.6 The Statins Market in Brazil, 2009-2021

7. Analysis of Factors Influencing the World Statins Market, 2011-2021

  • 7.1 SWOT Analysis of World Statins Market
  • 7.2 Drivers for and Restraints on Market Growth7.2.1 Market Drivers
  • 7.2.2 Market Restraints
  • 7.3 Outlook for the World Statins Market, 2011-2021
    • 7.3.1 Genericisation of the World Statins Market Will be a Restraint on Market Growth
    • 7.3.2 Governments and Insurers Will Favour Generic Statins
    • 7.3.3 Emerging Economies of India and China Will See Growth in Statin Sales
  • 7.4 Patient Compliance for Statin Medications
    • 7.4.1 Patients Exhibit Poor Compliance for Statin Medications
    • 7.4.2 Effective Contact between Patients and Healthcare Practitioners is the Key to Improving Patient Compliance
  • 7.5 Safety of Statins
  • 7.6 Statin OTC Switching
    • 7.6.1 Rationale for OTC Switching
    • 7.6.2 Statin OTC Switching in the UK
    • 7.6.3 Statin OTC Switching in the US
    • 7.6.4 What are the Prospects for Worldwide Statin OTC Switching?
  • 7.7 The Role of Clinical Trials in Expanding the Size of the World Statins Market

8. Research Interviews

  • 8.1 Interview with Dr Humayun J. Chaudhry, Commissioner of Health Services, Suffolk County, New York, USA
    • 8.1.1 Improving Patient Compliance in Statin Therapy
    • 8.1.2 The Future of Cholesterol Testing
    • 8.1.3 Web-Based Information Technology
  • 8.2 Interview with Professor Naveed Sattar, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK
    • 8.2.1 Current Research on the Therapeutic Effects of Statin Drugs
    • 8.2.2 Prospects for the Lipid-Lowering Drug Market after Lipitor Loses Patent Protection in 2011
    • 8.2.3 R&D Prospects within the Lipid-Lowering Field
    • 8.2.4 The Statin Pipeline

9. Statin and Non-Statin Lipid-Lowering R&D Pipeline

  • 9.1 The Statin R&D Pipeline Lacks New Single Statin Drugs
  • 9.2 Will CETP Inhibitors Succeed Statins as Blockbuster Drugs in the Lipid-Lowering Market?
  • 9.3 Statin/Non-Statin Combination Lipid-Lowering Pipeline
    • 9.3.1 Simvastatin/Fenofibrate
    • 9.3.2 Simvastatin/Rosiglitazone
  • 9.4 The Non-Statin Lipid-Lowering Pipeline
    • 9.4.1 Eicosapentaenoic Acid/Docosahexanoic Acid
    • 9.4.2 Eprotirome
    • 9.4.3 Anacetrapib
    • 9.4.4 Dalcetrapib
    • 9.4.5 Darapladib

10. Conclusions

  • 10.1 Statins Will Remain Vital Therapies for Treating Dyslipidaemia
  • 10.2 Future Challenges for the Statin Industry
    • 10.2.1 What are the Consequences of a Weak Statin R&D Pipeline?
    • 10.2.2 Increasing Patient Compliance is Vital for the Sustained Growth of the Statins Market
  • 10.3 By 2017, Sales of Generic Statins Will Outperform those of Branded Statins
  • 10.4 Emerging Markets of India and China Will See Growth in Statin Sales

List of Tables

  • Table 2.1: Risk Levels for Total Cholesterol, 2011
  • Table 2.2: Risk Levels for LDL Cholesterol, 2011
  • Table 2.3: Risk Levels for HDL Cholesterol, 2011
  • Table 2.4: Risk Levels for Triglycerides, 2011
  • Table 2.5: The Fredrickson/WHO Classification Scheme for Dyslipidaemia, 2011
  • Table 3.1: Leading Manufacturers of Generic Simvastatin, 2011
  • Table 3.2: Leading Manufacturers of Generic Pravastatin, 2011
  • Table 3.3: Leading Manufacturers of Generic Lovastatin, 2011
  • Table 4.1: Statin Lipid-Lowering Market Revenues ($bn) and Shares ($bn, %), 2009-2015
  • Table 4.2: Statin Lipid-Lowering Market Revenues ($bn) and Shares ($bn, %), 2016-2021
  • Table 4.3: Branded and Generic Statins: Market Revenues ($bn), 2009-2021
  • Table 5.1: World Lipid-Lowering Market Revenues ($bn), 2009
  • Table 5.2: World Sales ($bn) and Market Shares ($bn, %) for the Non-Statin Lipid-Lowering Market, 2009
  • Table 5.3: World Lipid-Lowering Market Revenues ($bn), 2009-2015
  • Table 5.4: World Lipid-Lowering Market Revenues ($bn), 2016-2021
  • Table 5.5: Revenues ($bn) of Leading Statins by Active Ingredient and Brand Names, 2009
  • Table 5.6: Branded and Generic Statins: Market Revenues ($bn), 2009 and 2021
  • Table 5.7: Branded and Generic Statins: Market Revenues ($bn), 2009-2015
  • Table 5.8: Branded and Generic Statins: Market Revenues ($bn), 2016-2021
  • Table 5.9: Statins Market Revenues ($bn) by Drug Class, 2009-2015
  • Table 5.10: Statins Market Revenues ($bn) by Drug Class, 2016-2021
  • Table 5.11: Atorvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
  • Table 5.12: Atorvastatin Drug Revenues ($bn), 2009-2015
  • Table 5.13: Atorvastatin Drug Revenues ($bn), 2016-2021
  • Table 5.14: Rosuvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
  • Table 5.15: Rosuvastatin Drug Revenues ($bn), 2009-2015
  • Table 5.16: Rosuvastatin Drug Revenues ($bn), 2016-2021
  • Table 5.17: Simvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
  • Table 5.18: Simvastatin Drug Revenues ($bn), 2009-2015
  • Table 5.19: Simvastatin Drug Revenues ($bn), 2016-2021
  • Table 5.20: Pravastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
  • Table 5.21: Pravastatin Drug Revenues ($bn), 2009-2015
  • Table 5.22: Pravastatin Drug Revenues ($bn), 2016-2021
  • Table 5.23: Fluvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
  • Table 5.24: Fluvastatin Drug Revenues ($bn), 2009-2015
  • Table 5.25: Fluvastatin Drug Revenues ($bn), 2016-2021
  • Table 5.26: Pitavastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
  • Table 5.27: Pitavastatin Drug Revenues ($bn), 2009-2015
  • Table 5.28: Pitavastatin Drug Revenues ($bn), 2016-2021
  • Table 5.29: Lovastatin Drug Revenues ($bn), 2009-2015
  • Table 5.30: Lovastatin Drug Revenues ($bn), 2016-2021
  • Table 5.31: Statin/Non-Statin Combination Drug Revenues ($bn) and Market Shares ($bn, %), 2009
  • Table 5.32: Statin/Non-Statin Combination Drug Revenues ($bn), 2009-2015
  • Table 5.33: Statin/Non-Statin Combination Drug Revenues ($bn), 2016-2021
  • Table 6.1: Revenues ($bn) of Statins in Leading National Markets, 2009
  • Table 6.2: Statins Revenues ($bn) in Leading National Markets, 2009-2015
  • Table 6.3: Statins Revenues ($bn) in Leading National Markets, 2016-2021
  • Table 7.1: SWOT Analysis of the Statins Market, 2011
  • Table 7.2: Expected Patent Expiries of Statins, 2009-2021
  • Table 9.1: Prominent Statin and Non-Statin Lipid-Lowering Agents in the R&D Pipeline, 2011

List of Figures

  • Figure 4.1: Lipitor Revenues ($bn), 2009-2021
  • Figure 4.2: Branded and Generic Statins: Market Revenues ($bn), 2009-2021
  • Figure 5.1: Market Share ($bn, %) in the Lipid-Lowering Market, 2009
  • Figure 5.2: World Lipid-Lowering Market Revenues ($bn), 2009-2021
  • Figure 5.3: Statin Market Shares ($bn, %) by Active Ingredient, 2009
  • Figure 5.4: Statin Market Shares ($bn, %) by Leading Brand, 2009
  • Figure 5.5: World Statin Market Revenues ($bn), 2009-2021
  • Figure 5.6: Branded and Generic Statins: Market Revenues ($bn), 2009-2021
  • Figure 5.7: Statins Market Revenues ($bn) by Drug Class, 2009-2021
  • Figure 5.8: Statins Market Shares ($bn, %) by Drug Class, 2009
  • Figure 5.9: Statins Market Shares ($bn, %) by Drug Class, 2015
  • Figure 5.10: Statins Market Shares ($bn, %) by Drug Class, 2021
  • Figure 5.11: Atorvastatin Drug Revenues ($bn), 2009-2021
  • Figure 5.12: Rosuvastatin Drug Revenues ($bn), 2009-2021
  • Figure 5.13: Simvastatin Drug Revenues ($bn), 2009-2021
  • Figure 5.14: Pravastatin Drug Revenues ($bn), 2009-2021
  • Figure 5.15: Fluvastatin Drug Revenues ($bn), 2009-2021
  • Figure 5.16: Pitavastatin Drug Revenues ($bn), 2009-2021
  • Figure 5.17: Lovastatin Drug Revenues ($bn), 2009-2021
  • Figure 5.18: Statin/Non-Statin Combination Drug Revenues ($bn), 2009-2021
  • Figure 6.1: Statin Drug Revenues ($bn) in Leading National Markets, 2009
  • Figure 6.2: Market Shares ($bn, %) of the World Statins Market by Country, 2009
  • Figure 6.3: The US Statins Market ($bn), 2009-2021
  • Figure 6.4: Market Shares ($bn, %) of the World Statins Market by Country, 2021
  • Figure 6.5: The Japanese Statins Market ($bn), 2009-2021
  • Figure 6.6: The Canadian Statins Market ($bn), 2009-2021
  • Figure 6.7: The Leading European Statins Markets ($bn), 2009-2021
  • Figure 6.8: Statins Markets ($bn) in India and China, 2009-2021
  • Figure 6.9: The Brazilian Statins Market ($bn), 2009-2021
  • Figure 10.1: Branded and Generic Statins: Revenues ($bn), 2009-2021

Companies Listed

  • Abbott
  • Actavis
  • Almirall
  • Alter
  • American Heart Association
  • American Medical Association
  • Apotex
  • Astellas
  • AstraZeneca
  • Bago
  • Bristol-Myers Squibb
  • British Heart Foundation Glasgow Cardiovascular Centre
  • Chiesi
  • CINFA
  • Cholesterol Treatment Trialists' Collaboration
  • Choongwae
  • Cobalt Laboratories
  • Cobalt Pharmaceuticals
  • Cochrane Library
  • Covidien
  • Daiichi Sankyo
  • Dr. Reddy' s Laboratories
  • Eli Lilly
  • Esteve
  • European Medicines Agency (EMA)
  • European Society of Cardiology
  • Ferrer
  • Food and Drug Administration (FDA)
  • Forest Laboratories
  • Gedeon Richter
  • Genzyme
  • GlaxoSmithKline (GSK)
  • Glenmark
  • Human Genome Sciences
  • Intas
  • Japan Tobacco
  • Johnson & Johnson
  • Karo Bio
  • Kowa Pharmaceuticals
  • Krka
  • London School of Hygiene and Tropical Medicine
  • Lupin
  • Lundbeck
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medley Pharmaceuticals
  • Menarini
  • Merck & Co.
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Mylan
  • National Health Service (NHS)
  • National Heart Lung and Blood Institute (NHLBI)
  • National Institute for Clinical Excellence (NICE)
  • National Institutes of Health (NIH)
  • Nissan Chemical
  • Nichi-Iko
  • Novartis
  • Omthera
  • Par Pharmaceutical
  • Pfizer
  • Pierre Fabre
  • Polypharma
  • Public Citizen
  • Ranbaxy Laboratories
  • Ratiopharm
  • Recordati Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi-Aventis
  • Sawai
  • Sunovion
  • Servier
  • Schering-Plough
  • Shionogi & Co.
  • Sigma Pharmaceuticals
  • Sigma-Tau Pharmaceuticals
  • Solvay
  • Stada
  • Takeda
  • Teva Pharmaceuticals
  • University of Birmingham
  • University of Bristol
  • University of Glasgow
  • University of Oxford
  • Watson Pharmaceuticals
  • World Health Organization (WHO)
  • Wyeth
  • Zentiva
  • Zydus Cadila
Back to Top